- Home
- PULM vs APM Comparison
PULM vs APM Comparison
Compare PULM & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- APM
- Stock Information
- Founded
- PULM 2003
- APM 2010
- Country
- PULM United States
- APM United Kingdom
- Employees
- PULM N/A
- APM N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- PULM Health Care
- APM Health Care
- Exchange
- PULM Nasdaq
- APM Nasdaq
- Market Cap
- PULM 18.3M
- APM 18.9M
- IPO Year
- PULM N/A
- APM 2018
- Fundamental
- Price
- PULM $4.87
- APM $1.48
- Analyst Decision
- PULM
- APM
- Analyst Count
- PULM 0
- APM 0
- Target Price
- PULM N/A
- APM N/A
- AVG Volume (30 Days)
- PULM 17.6K
- APM 337.0K
- Earning Date
- PULM 10-16-2025
- APM 04-30-2025
- Dividend Yield
- PULM N/A
- APM N/A
- EPS Growth
- PULM N/A
- APM N/A
- EPS
- PULM N/A
- APM N/A
- Revenue
- PULM $3,000.00
- APM N/A
- Revenue This Year
- PULM N/A
- APM N/A
- Revenue Next Year
- PULM $134.88
- APM N/A
- P/E Ratio
- PULM N/A
- APM N/A
- Revenue Growth
- PULM N/A
- APM N/A
- 52 Week Low
- PULM $2.00
- APM $0.46
- 52 Week High
- PULM $10.40
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- PULM 50.82
- APM 40.46
- Support Level
- PULM $4.55
- APM $1.43
- Resistance Level
- PULM $4.95
- APM $1.59
- Average True Range (ATR)
- PULM 0.21
- APM 0.17
- MACD
- PULM 0.02
- APM -0.03
- Stochastic Oscillator
- PULM 46.72
- APM 7.98
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.